A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

References

• MoffittTEHoutsRAshersonPIs adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort studyAm J Psychiatry20151721096797725998281
   PubMed Web of Science ®Google Scholar
• WillcuttEGThe prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic reviewNeurotherapeutics20129349049922976615
   PubMed Web of Science ®Google Scholar
• DopheideJAPliszkaSRAttention-deficit-hyperactivity disorder: an updatePharmacotherapy200929665667919476419
   PubMed Web of Science ®Google Scholar
• BrodMPohlmanBLasserRHodgkinsPComparison of the burden of illness for adults with ADHD across seven countries: a qualitative studyHealth Qual Life Outcomes2012104722583562
   PubMed Web of Science ®Google Scholar
• FaraoneSVBiedermanJMickEThe age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studiesPsychol Med200636215916516420712
   PubMed Web of Science ®Google Scholar
• AdlerLASpencerTBrownTEOnce-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trialJ Clin Psychopharmacol2009291445019142107
   PubMed Web of Science ®Google Scholar
• UpadhyayaHAdlerLACasasMBaseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetineChild Adolesc Psychiatry Ment Health2013711423648011
   PubMed Web of Science ®Google Scholar
• JensenCMSteinhausenHCComorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide studyAtten Defic Hyperact Disord201571273824942707
   PubMedGoogle Scholar
• KesslerRCAdlerLBarkleyRThe prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey ReplicationAm J Psychiatry2006163471672316585449
   PubMed Web of Science ®Google Scholar
• LarsonKRussSAKahnRSHalfonNPatterns of comorbidity, functioning, and service use for US children with ADHD, 2007Pediatrics2011127346247021300675
   PubMed Web of Science ®Google Scholar
• NewcornJHWeissMSteinMAThe complexity of ADHD: diagnosis and treatment of the adult patient with comorbiditiesCNS Spectr2007128 Suppl 12114
   Web of Science ®Google Scholar
• GellerDDonnellyCLopezFAtomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorderJ Am Acad Child Adolesc Psychiatry20074691119112717712235
   PubMed Web of Science ®Google Scholar
• SciberrasELycettKEfronDMensahFGernerBHiscockHAnxiety in children with attention-deficit/hyperactivity disorderPediatrics2014133580180824753534
   PubMed Web of Science ®Google Scholar
• BakkenRJPaczkowskiMKramerHPEffects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic studyCurr Med Res Opin200824244946018179733
   PubMed Web of Science ®Google Scholar
• ReinblattSPLeoutsakosJMMahoneEMForresterSWilcoxHCRiddleMAAssociation between binge eating and attention-deficit/hyperactivity disorder in two pediatric community mental health clinicsInt J Eat Disord201548550551125130278
   PubMed Web of Science ®Google Scholar
• TaurinesRSchmittJRennerTConnerACWarnkeARomanosMDevelopmental comorbidity in attention-deficit/hyperactivity disorderAtten Defic Hyperact Disord20102426728921432612
   PubMedGoogle Scholar
• SinghMKDelBelloMPKowatchRAStrakowskiSMCo-occurrence of bipolar and attention-deficit hyperactivity disorders in childrenBipolar Disord20068671072017156157
   PubMed Web of Science ®Google Scholar
• BiedermanJSpencerTJNewcornJHEffect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial dataPsychopharmacology (Berl)20071901314117093981
   PubMed Web of Science ®Google Scholar
• GillbergCGillbergICRasmussenPCo-existing disorders in ADHD – implications for diagnosis and interventionEur Child Adolesc Psychiatry200413Suppl 1I80I9215322959
   PubMedGoogle Scholar
• ReichowBVolkmarFRBlochMHSystematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disordersJ Autism Dev Disord201343102435244123468071
   PubMed Web of Science ®Google Scholar
• KollinsSHADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelinesJ Atten Disord200812211512518192623
   PubMed Web of Science ®Google Scholar
• McGoughJJSmalleySLMcCrackenJTPsychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex familiesAm J Psychiatry200516291621162716135620
   PubMed Web of Science ®Google Scholar
• BiedermanJAttention-deficit/hyperactivity disorder: a life-span perspectiveJ Clin Psychiatry199859Suppl 7416
   PubMed Web of Science ®Google Scholar
• Ramos-QuirogaJANasilloVFernández-ArandaFCasasMAddressing the lack of studies in attention-deficit/hyperactivity disorder in adultsExpert Rev Neurother201414555356724738746
   PubMed Web of Science ®Google Scholar
• WilensTEMorrisonNRPrinceJAn update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsExpert Rev Neurother201111101443146521955201
   PubMed Web of Science ®Google Scholar
• PerugiGVannucchiGThe use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorderExpert Opin Pharmacother201516142193220426364896
   PubMed Web of Science ®Google Scholar
• WingoAPGhaemiSNA systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorderJ Clin Psychiatry200768111776178418052572
   PubMed Web of Science ®Google Scholar
• KolarDKellerAGolfinopoulosMCumynLSyerCHechtmanLTreatment of adults with attention-deficit/hyperactivity disorderNeuropsychiatr Dis Treat20084238940318728745
   PubMedGoogle Scholar
• BiedermanJAttention-deficit/hyperactivity disorder: a selective overviewBiol Psychiatry200557111215122015949990
   PubMed Web of Science ®Google Scholar
• Adderall^® (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate tablets) [prescribing information]Horsham, PATeva Pharmaceuticals USA2015
   Google Scholar
• Ritalin^® (methylphenidate hydrochloride tablets) [prescribing information]Gainesville, GANovartis Pharmaceuticals Corporation2007
   Google Scholar
• Ritalin^® (methylphenidate hydrochloride tablets) [summary of product characteristics]SurreyNovartis Pharmaceuticals UK Ltd2015
   Google Scholar
• FeltBTBiermannBChristnerJGKochharPHarrisonRVDiagnosis and management of ADHD in childrenAm Fam Physician201490745646425369623
   PubMed Web of Science ®Google Scholar
• CoughlinCGCohenSCMulqueenJMFerracioli-OdaEStuckelmanZDBlochMHMeta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorderJ Child Adolesc Psychopharmacol201525861161726402485
   PubMed Web of Science ®Google Scholar
• BangsMETauscher-WisniewskiSPolzerJMeta-analysis of suicide-related behavior events in patients treated with atomoxetineJ Am Acad Child Adolesc Psychiatry200847220921818176331
   PubMed Web of Science ®Google Scholar
• Garnock-JonesKPKeatingGMAtomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescentsPaediatr Drugs200911320322619445548
   PubMedGoogle Scholar
• Strattera^® (atomoxetine capsules) [strattera prescribing information]Indianapolis, INEli Lilly and Company2009
   Google Scholar
• Strattera^® (atomoxetine capsules) [strattera summary of product characteristics]HampshireEli Lilly and Company Ltd2015
   Google Scholar
• WilensTEImpact of ADHD and its treatment on substance abuse in adultsJ Clin Psychiatry200465Suppl 3384515046534
   PubMed Web of Science ®Google Scholar
• Bolea-AlamañacBNuttDJAdamouMBritish Association for PsychopharmacologyEvidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201428317920324526134
   PubMed Web of Science ®Google Scholar
• Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA)Pharmacological treatment of ADHDCanadian ADHD Practice Guidelines3rd ed.Toronto, ONCADDRA2014
   Google Scholar
• WeissMDWeissJRA guide to the treatment of adults with ADHDJ Clin Psychiatry200465Suppl 32737
   PubMed Web of Science ®Google Scholar
• BusheCDayKReedVA network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patientsJ Psychopharmacol201630544445827005307
   PubMed Web of Science ®Google Scholar
• BusheCJSavillNCSystematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safetyJ Psychopharmacol201428320421123438503
   PubMed Web of Science ®Google Scholar
• ClemowDBBusheCJAtomoxetine in patients with ADHD: a clinical and pharmacological review of the onset, trajectory, duration of response and implications for patientsJ Psychopharmacol201529121221123026349559
   PubMed Web of Science ®Google Scholar
• KratochvilCJNewcornJHArnoldLEAtomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptomsJ Am Acad Child Adolesc Psychiatry200544991592416113620
   PubMed Web of Science ®Google Scholar
• ChangKNayarDHoweMRanaMAtomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorderJ Child Adolesc Psychopharmacol200919554755119877979
   PubMed Web of Science ®Google Scholar
• HahMChangKAtomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disordersJ Child Adolesc Psychopharmacol2005156996100416379520
   PubMed Web of Science ®Google Scholar
• NewcornJHSpencerTJBiedermanJMiltonDRMichelsonDAtomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorderJ Am Acad Child Adolesc Psychiatry200544324024815725968
   PubMed Web of Science ®Google Scholar
• BangsMEHazellPDanckaertsMAtomoxetine ADHD/ODD Study GroupAtomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorderPediatrics20081212e314e32018245404
   PubMed Web of Science ®Google Scholar
• DittmannRWSchachtAHelsbergKAtomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in GermanyJ Child Adolesc Psychopharmacol20112129711021488751
   PubMed Web of Science ®Google Scholar
• Dell’AgnelloGMaschiettoDBravaccioCLYCY Study GroupAtomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian studyEur Neuropsychopharmacol2009191182283419716683
   PubMed Web of Science ®Google Scholar
• GargJArunPChavanBSComparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorderInt J Appl Basic Med Res20155211411826097819
   PubMedGoogle Scholar
• ChengJYChenRYKoJSNgEMEfficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysisPsychopharmacology (Berl)2007194219720917572882
   PubMed Web of Science ®Google Scholar
• WehmeierPMSchachtADittmannRWEffect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorderQual Life Res201120569170221136299
   PubMed Web of Science ®Google Scholar
• WaxmonskyJGWaschbuschDAAkinnusiOPelhamWEA comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorderJ Child Adolesc Psychopharmacol2011211213221288121
   PubMed Web of Science ®Google Scholar
• van WykGWHazellPLKohnMRGrangerREWaltonRJHow oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysisJ Atten Disord201216431432421289234
   PubMed Web of Science ®Google Scholar
• WehmeierPMKippLBanaschewskiTDittmannRWSchachtADoes comorbid disruptive behavior modify the effects of atomoxetine on ADHD symptoms as measured by a continuous performance test and a motion tracking device?J Atten Disord201519759160222930789
   PubMed Web of Science ®Google Scholar
• ErcanESAkyol ArdicUKabukcu BasayBErcanEBasayOAtomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart reviewAtten Defic Hyperact Disord20135437738523737214
   PubMedGoogle Scholar
• KaplanSHeiligensteinJWestSEfficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorderJ Atten Disord200482455215801334
   PubMedGoogle Scholar
• HazellPZhangSWolanczykTComorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderEur Child Adolesc Psychiatry200615210511016523251
   PubMed Web of Science ®Google Scholar
• ScottNGRipperger-SuhlerJRajabMHKjarDFactors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescentsJ Child Adolesc Psychopharmacol201020319720320578932
   PubMed Web of Science ®Google Scholar
• BangsMEEmslieGJSpencerTJAtomoxetine ADHD and Comorbid MDD Study GroupEfficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depressionJ Child Adolesc Psychopharmacol200717440742017822337
   PubMed Web of Science ®Google Scholar
• WietechaLWilliamsDShaywitzSAtomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trialJ Child Adolesc Psychopharmacol201323960561324206099
   PubMed Web of Science ®Google Scholar
• de JongCGVan De VoordeSRoeyersHDifferential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorderJ Child Adolesc Psychopharmacol200919669970720035588
   PubMed Web of Science ®Google Scholar
• SumnerCRGathercoleSGreenbaumMAtomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children with ADHD and dyslexiaChild Adolesc Psychiatry Ment Health200934020003507
   PubMedGoogle Scholar
• ShaywitzBAWilliamsDWFoxBKWietechaLAReading outcomes of children and adolescents with attention-deficit/hyperactivity disorder and dyslexia following atomoxetine treatmentJ Child Adolesc Psychopharmacol201424841942525299355
   PubMed Web of Science ®Google Scholar
• ArnoldLEAmanMGCookAMAtomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trialJ Am Acad Child Adolesc Psychiatry200645101196120517003665
   PubMed Web of Science ®Google Scholar
• HarfterkampMvan de Loo-NeusGMinderaaRBA randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorderJ Am Acad Child Adolesc Psychiatry201251773374122721596
   PubMed Web of Science ®Google Scholar
• HarfterkampMBuitelaarJKMinderaaRBvan de Loo-NeusGvan der GaagRJHoekstraPJLong-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension studyJ Child Adolesc Psychopharmacol201323319419923578015
   PubMed Web of Science ®Google Scholar
• TroostPWSteenhuisMPTuynman-QuaHGAtomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot studyJ Child Adolesc Psychopharmacol200616561161917069549
   PubMed Web of Science ®Google Scholar
• Fernández-JaénAFernández-MayoralasDMCalleja-PérezBMuñoz-JareñoNCampos DíazMRLópez-ArribasSEfficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: a prospective, open-label studyJ Atten Disord201317649750522366240
   PubMed Web of Science ®Google Scholar
• JouRJHandenBLHardanAYRetrospective assessment of atomoxetine in children and adolescents with pervasive developmental disordersJ Child Adolesc Psychopharmacol200515232533015910217
   PubMed Web of Science ®Google Scholar
• PoseyDJWiegandREWilkersonJMaynardMStiglerKAMcDougleCJOpen-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disordersJ Child Adolesc Psychopharmacol200616559961017069548
   PubMed Web of Science ®Google Scholar
• CharnsilCEfficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label studyJ Atten Disord201115868468920686100
   PubMed Web of Science ®Google Scholar
• SangalRBOwensJAllenAJSuttonVSchuhKKelseyDEffects of atomoxetine and methylphenidate on sleep in children with ADHDSleep200629121573158517252888
   PubMed Web of Science ®Google Scholar
• ThurstoneCRiggsPDSalomonsen-SautelSMikulich-GilbertsonSKRandomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorderJ Am Acad Child Adolesc Psychiatry201049657358220494267
   PubMed Web of Science ®Google Scholar
• AllenAJKurlanRMGilbertDLAtomoxetine treatment in children and adolescents with ADHD and comorbid tic disordersNeurology200565121941194916380617
   PubMed Web of Science ®Google Scholar
• SpencerTJSalleeFRGilbertDLAtomoxetine treatment of ADHD in children with comorbid Tourette syndromeJ Atten Disord200811447048117934184
   PubMed Web of Science ®Google Scholar
• AdlerLARubinRQiaoMHeinlothANDurellTMPatient characteristics and treatment response to atomoxetine in adults with ADHD versus ADHD comorbid with social anxiety disorderJ ADHD Relat Disord201013515
   Google Scholar
• AdlerLALiebowitzMKronenbergerWAtomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorderDepress Anxiety200926321222119194995
   PubMed Web of Science ®Google Scholar
• DonnellyCLAdlerLAQiaoMDurellTMAnxiety response to atomoxetine in patients with attention-deficit/hyperactivity disorder and comorbid anxietyPoster presented at: 23rd Annual U.S. Psychiatric and Mental Health Congress (USPMHC)November 18, 2010Orlando, FL
   Google Scholar
• RavindranLNKimDSLetamendiAMSteinMBA randomized controlled trial of atomoxetine in generalized social anxiety disorderJ Clin Psychopharmacol200929656156419910721
   PubMed Web of Science ®Google Scholar
• GabrielAViolatoCAdjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label studyAtten Defic Hyperact Disord20113431932621833565
   PubMedGoogle Scholar
• YoungJLSarkisEQiaoMWietechaLOnce-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trialClin Neuropharmacol2011342516021406998
   PubMed Web of Science ®Google Scholar
• DurellTMAdlerLAWilliamsDWAtomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trialJ Clin Psychopharmacol2013331455423277268
   PubMed Web of Science ®Google Scholar
• WilensTEAdlerLAWeissMDAtomoxetine ADHD/SUD Study GroupAtomoxetine treatment of adults with ADHD and comorbid alcohol use disordersDrug Alcohol Depend2008961–214515418403134
   PubMed Web of Science ®Google Scholar
• WilensTEAdlerLATanakaYCorrelates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetineCurr Med Res Opin201127122309232022029549
   PubMed Web of Science ®Google Scholar
• BenegalVViswanathBNarayanaswamyJCThe efficacy of atomoxetine as adjunctive treatment for co-morbid substance use disorders and externalizing symptomsAsian J Psychiatry201366544547
   Google Scholar
• AdlerLAGuidaFIronsSShawDMOpen label pilot study of atomoxetine in adults with ADHD and substance use disorderJ Dual Diagn201063–4196207
   Web of Science ®Google Scholar
• LevinFRMarianiJJSecoraAAtomoxetine treatment for cocaine abuse and adult attention-deficit hyperactivity disorder (ADHD): a preliminary open trialJ Dual Diagn200951415619430599
   PubMed Web of Science ®Google Scholar
• McRae-ClarkALCarterREKilleenTKCarpenterMJWhiteKGBradyKTA placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorderAm J Addict201019648148920958842
   PubMed Web of Science ®Google Scholar
• LiuXKubilisPXuDBussingRWintersteinAGPsychotropic drug utilization in children with concurrent attention-deficit/hyperactivity disorder and anxietyJ Anxiety Disord201428653053624981018
   PubMed Web of Science ®Google Scholar
• KuhneMSchacharRTannockRImpact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorderJ Am Acad Child Adolesc Psychiatry19973612171517259401333
   PubMed Web of Science ®Google Scholar
• BeckerSPMarshallSAMcBurnettKSluggish cognitive tempo in abnormal child psychology: an historical overview and introduction to the special sectionJ Abnorm Child Psychol20144211624272365
   PubMed Web of Science ®Google Scholar
• OwensJSangalRBSuttonVKBakkenRAllenAJKelseyDSubjective and objective measures of sleep in children with attention-deficit/hyperactivity disorderSleep Med200910444645618693137
   PubMed Web of Science ®Google Scholar
• TsangTWKohnMREfronDAnxiety in young people with ADHD: clinical and self-report outcomesJ Atten Disord2015191182622713359
   PubMed Web of Science ®Google Scholar
• ClemowDBWalkerDJThe potential for misuse and abuse of medications in ADHD: a reviewPostgrad Med20141265648125295651
   PubMed Web of Science ®Google Scholar
• HutchisonSLGhumanJKGhumanHSKarpovISchusterJMEfficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a reviewTher Adv Psychopharmacol20166531733427721971
   PubMed Web of Science ®Google Scholar
• WalkerDJMasonOClemowDBDayKAAtomoxetine treatment in adults with attention-deficit/hyperactivity disorderPostgrad Med2015127768670126343377
   PubMed Web of Science ®Google Scholar
• JerrellJMMcIntyreRSParkYMRisk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorderEur Child Adolesc Psychiatry2015241657324705730
   PubMed Web of Science ®Google Scholar
• McIntyreRSKennedySHSoczynskaJKAttention-deficit/hyperactivity disorder in adults with bipolar disorder or major depressive disorder: results from the international mood disorders collaborative projectPrim Care Companion J Clin Psychiatry2010123e1e7
   Google Scholar
• Dell’OssoBPalazzoMCOldaniLAltamuraACThe noradrenergic action in antidepressant treatments: pharmacological and clinical aspectsCNS Neurosci Ther201117672373221155988
   PubMed Web of Science ®Google Scholar
• ChouinardGAnnableLBradwejnJAn early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patientsPsychopharmacology (Berl)19848311261286429697
   PubMed Web of Science ®Google Scholar
• BlierPPsychopharmacology for the Clinician Psychopharmacologie pratiqueJ Psychiatry Neurosci200631428816862246
   PubMed Web of Science ®Google Scholar
• MichelsonDAdlerLAAmsterdamJDAddition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768458258717474814
   PubMed Web of Science ®Google Scholar
• CorteseSHoltmannMBanaschewskiTEuropean ADHD Guidelines GroupPractitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescentsJ Child Psychol Psychiatry201354322724623294014
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceClinical guideline 72: attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults2013
   Google Scholar
• KatusicSKBarbaresiWJColliganRCWeaverALLeibsonCLJacobsenSJPsychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort studyJ Child Adolesc Psychopharmacol200515576477616262593
   PubMed Web of Science ®Google Scholar
• KollinsSHA qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disordersCurr Med Res Opin20082451345135718384709
   PubMed Web of Science ®Google Scholar
• UpadhyayaHPDesaiahDSchuhKJA review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorderPsychopharmacology (Berl)2013226218920023397050
   PubMed Web of Science ®Google Scholar
• WolraichMBrownLBrownRTSubcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and ManagementADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescentsPediatrics201112851007102222003063
   PubMed Web of Science ®Google Scholar
• PliszkaSAACAP Work Group on Quality IssuesPractice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorderJ Am Acad Child Adolesc Psychiatry200746789492117581453
   PubMed Web of Science ®Google Scholar
• BrewertonTDDuncanAEAssociations between attention deficit hyperactivity disorder and eating disorders by gender: results from the national comorbidity survey replicationEur Eat Disord Rev201624653654027480884
   PubMed Web of Science ®Google Scholar
• AshersonPYoungAHEich-HöchliDMoranPPorsdalVDeberdtWDifferential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adultsCurr Med Res Opin20143081657167224804976
   PubMed Web of Science ®Google Scholar